The Pacific Ovarian Cancer Research Consortium (POCRC) is a community-based, multidisciplinary, translational research program that involves clinicians, laboratory scientists and public health scientists from six research and medical institutions on the Pacific Coast. The community-based approach allows the pooling of clinical resources to facilitate population-based studies despite the low incidence of ovarian cancer. The themes of the program are biomarkers for risk and early detection of disease, molecular targets for prognosis and therapy, and antigens for immunotherapy. We hypothesize that through early detection we can improve outcomes significantly because currently available treatments are more effective in disease confined to the ovary;new, less toxic immunotherapeutic approaches are expected to be particularly effective in early-stage disease. The POCRC will conduct 5 translational research projects including a screening trial in high-risk women using serum markers validated in preclinical samples, a novel imaging trial using targeted microbubbles to improve ultrasound performance, validation of a microRNA plasma signature for respectability, exploration of restoration of wild-type BRCA1 function in the development of resistance to cicplatin, and a Phase 1 trial of an anti-lGFBP2 vaccine. Each project addresses at least one of the translational areas outlined in the SPORE guidelines and together the program addresses 5 of the 6 translational pathways defined by the TRWG, All projects build on work performed during the current and previous funding periods. A Developmental Research Program and a Career Development Program are also included as part of our Renewal. Projects are supported by a Leadership and Administration Core, a Clinical Specimen Management and Characterization Core, a Participant Recruitment, Enrollment and Characterization Core, and a Biostatistics and Data Management Core.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Arnold, Julia T
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Wang, Yifan; Krais, John J; Bernhardy, Andrea J et al. (2016) RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance. J Clin Invest 126:3145-57
Norquist, Barbara M; Harrell, Maria I; Brady, Mark F et al. (2016) Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol 2:482-90
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2016) Selenium Binding Protein 1 autoantibodies in ovarian disorders and ovarian cancer. Reproduction :
Yumul, Roma; Richter, Maximilian; Lu, Zhuo-Zhuang et al. (2016) Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models. Hum Gene Ther 27:325-37
Wang, Yifan; Bernhardy, Andrea J; Cruz, Cristina et al. (2016) The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res 76:2778-90
Andersen, M Robyn; Thorpe, Jason; Buist, Diana S M et al. (2016) Cancer Risk Awareness and Concern among Women with a Family History of Breast or Ovarian Cancer. Behav Med 42:18-28
Buas, Matthew F; Gu, Haiwei; Djukovic, Danijel et al. (2016) Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors. Gynecol Oncol 140:138-44
Elias, Kevin M; Emori, Megan M; Westerling, Thomas et al. (2016) Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors. JCI Insight 1:
Gregory, Mark T; Bertout, Jessica A; Ericson, Nolan G et al. (2016) Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Res 44:e22
Bernards, Sarah S; Norquist, Barbara M; Harrell, Maria I et al. (2016) Genetic characterization of early onset ovarian carcinoma. Gynecol Oncol 140:221-5

Showing the most recent 10 out of 167 publications